Connect to other sites within the UBM Medica Network
FDA Approves First MR Contrast Agent for Breast Cancer Evaluation
The FDA has given Bayer’s Gadavist approval for use with MRI of the breast to evaluate malignant breast disease.
Trust Me, I’m a Radiologist
Radiologists tend to get a bad rap, but when it comes to imaging studies, we know best.
FDA Approves SOMATOM Force CT System by Siemens
The latest dual source CT includes features that provide low dose imaging for patients with renal insufficiency, difficulty holding their breath and more.
Preparing Clinicians for Managing Adverse Contrast Reaction
Didactic module helps prepare clinicians for managing adverse reactions to media, more training still needed.
Necessary CTs Should Not Be Delayed in Patients with CRM Devices
Study provides no additional evidence supporting 2008 FDA advisory that warned CT scans potentially interfere with CRM devices.
Risk of Acute Kidney Injury Independent of Contrast Use
Patients who underwent CT with or without contrast had similar rates of acute kidney injury, showing contrast use isn’t associated with nephropathy.
Gadolinium-based Contrast Linked to Brain Abnormalities
Frequent use of gadolinium-based contrast medium may play a role in hypersensitivity in the brain of patients who undergo multiple MRIs.
PET Imaging with Amyvid for Alzheimer's
Video: Roberto Soto, MD, discusses using PET imaging with Amyvid for Alzheimer’s evaluation, including reimbursement, training, and benefits of the new test.
Case Study: PET Imaging with Amyvid for Alzheimer’s
Video: Roberto Soto, MD, of Precision Imaging, shows a recent PET imaging case using Amyvid, recently approved for evaluation of Alzheimer's.
By clicking Accept, you agree to become a member of the UBM Medica Community.